Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention

References

• Federation ID. IDF Diabetes Atlas. 2021.
   Google Scholar
• Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143(6):540–552.
   PubMed Web of Science ®Google Scholar
• Shim K, Begum R, Yang C, et al. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. World J Diabetes. 2020;11(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kao MPC, Ang DSC, Pall A, et al. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens. 2010;24(1):1–8.
   PubMed Web of Science ®Google Scholar
• Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care. 2002;5(5):561–568.
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820.
   PubMed Web of Science ®Google Scholar
• Tilton RG, Chang K, Nyengaard JR, et al. Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes. 1995;44(2):234–242.
   PubMed Web of Science ®Google Scholar
• Garg SS, Gupta J. Polyol pathway and redox balance in diabetes. Pharmacol Res. 2022;182:106326.
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu Z, Ying K, et al. WJ-39, an aldose reductase inhibitor, ameliorates renal lesions in diabetic nephropathy by activating Nrf2 signaling. Oxid Med Cell Longev. 2020;2020:7950457.
   PubMed Web of Science ®Google Scholar
• Kawarada Y, Inoue Y, Kawasaki F, et al. TGF-β induces p53/smads complex formation in the PAI-1 promoter to activate transcription. Sci Rep. 2016;6:35483.
   PubMed Web of Science ®Google Scholar
• Yonekura H, Yamamoto Y, Sakurai S, et al. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci. 2005;97(3):305–311.
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995;96(3):1395–1403.
   PubMed Web of Science ®Google Scholar
• Singh LP, Cheng DW, Kowluru R, et al. Hexosamine induction of oxidative stress, hypertrophy and laminin expression in renal mesangial cells: effect of the anti-oxidant alpha-lipoic acid. Cell Biochem Funct. 2007;25(5):537–550.
   PubMed Web of Science ®Google Scholar
• Yi H, Juhong Y. Relationship between OGlcNAcylation and diabetic nephropathy. Chin J Diabetes. 2021;13(03):282–286.
   PubMedGoogle Scholar
• Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes. 2008;57(2):460–469.
   PubMed Web of Science ®Google Scholar
• Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov. 2012;11(12):937–957.
   PubMed Web of Science ®Google Scholar
• Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799.
   PubMed Web of Science ®Google Scholar
• Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, et al. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018;9(2):119.
   PubMed Web of Science ®Google Scholar
• Sharma K, Danoff TM, DePiero A, et al. Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. Biochem Biophys Res Commun. 1995;207(1):80–88.
   PubMed Web of Science ®Google Scholar
• Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J Clin Invest. 1992;89(5):1496–1500.
   PubMed Web of Science ®Google Scholar
• Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106(8):1319–1331.
   PubMed Web of Science ®Google Scholar
• Jha JC, Dai A, Garzarella J, et al. Independent of renox, NOX5 promotes renal inflammation and fibrosis in diabetes by activating ROS-Sensitive pathways. Diabetes. 2022;71(6):1282–1298.
   PubMed Web of Science ®Google Scholar
• Wang R, Song F, Li S, et al. Salvianolic acid a attenuates CCl(4)-induced liver fibrosis by regulating the PI3K/AKT/mTOR, Bcl-2/bax and caspase-3/cleaved caspase-3 signaling pathways. Drug Des Devel Ther. 2019;13:1889–1900.
   PubMed Web of Science ®Google Scholar
• Hay N. Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta. 2011;1813(11):1965–1970.
   PubMed Web of Science ®Google Scholar
• Ying C, Mao Y, Chen L, et al. Bamboo leaf extract ameliorates diabetic nephropathy through activating the AKT signaling pathway in rats. Int J Biol Macromol. 2017;105(Pt 3):1587–1594.
   PubMedGoogle Scholar
• Guo J, Liu Z, Gong R. Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease. Clin Sci. 2019;133(12):1321–1339.
   PubMed Web of Science ®Google Scholar
• Bolós V, Peinado H, Pérez-Moreno MA, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116(Pt 3):499–511.
   PubMed Web of Science ®Google Scholar
• Lu Q, Wang W-W, Zhang M-Z, et al. ROS induces epithelial-mesenchymal transition via the TGF-β1/PI3K/Akt/mTOR pathway in diabetic nephropathy. Exp Ther Med. 2019;17(1):835–846.
   PubMed Web of Science ®Google Scholar
• Qing Y, Dong X, Hongli L, et al. Berberine promoted myocardial protection of postoperative patients through regulating myocardial autophagy. Biomed Pharmacother. 2018;105:1050–1053.
   PubMed Web of Science ®Google Scholar
• Barthel A, Schmoll D, Unterman TG. FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab. 2005;16(4):183–189.
   PubMed Web of Science ®Google Scholar
• Li W, Wang Q, Du M, et al. Effects of overexpressing FoxO1 on apoptosis in glomeruli of diabetic mice and in podocytes cultured in high glucose medium. Biochem Biophys Res Commun. 2016;478(2):612–617.
   PubMed Web of Science ®Google Scholar
• Qin G, Zhou Y, Guo F, et al. Overexpression of the FoxO1 ameliorates mesangial cell dysfunction in male diabetic rats. Mol Endocrinol. 2015;29(7):1080–1091.
   PubMedGoogle Scholar
• Ke-Ke M, et al. Effect of astragaloside IV on regulation of PI3K/akt/FoxO1 signal in kidney of type 2 diabetic nephropathy rats. Chin J Exp Trad Med Formulae. 2019;25(02):74–81.
   Google Scholar
• Wen C, Ying Y, Zhao H, et al. Resistance exercise affects catheter-related thrombosis in rats through miR-92a-3p, oxidative stress and the MAPK/NF-κB pathway. BMC Cardiovasc Disord. 2021;21(1):440.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F. Nonproteinuric progressive diabetic kidney disease. Curr Opin Nephrol Hypertens. 2019;28(3):227–232.
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Schiekofer S, Isermann B, et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia. 1999;42(2):222–232.
   PubMed Web of Science ®Google Scholar
• Zheng H, Whitman SA, Wu W, et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes. 2011;60(11):3055–3066.
   PubMed Web of Science ®Google Scholar
• Jiang T, Huang Z, Lin Y, et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes. 2010;59(4):850–860.
   PubMed Web of Science ®Google Scholar
• Ma L, Wu F, Shao Q, et al. Baicalin alleviates oxidative stress and inflammation in diabetic nephropathy via Nrf2 and MAPK signaling pathway. Drug Des Devel Ther. 2021;15:3207–3221.
   PubMed Web of Science ®Google Scholar
• Sen Z, Weida W, Jie M, et al. Coumarin glycosides from Hydrangea paniculata slow down the progression of diabetic nephropathy by targeting Nrf2 anti-oxidation and smad2/3-mediated profibrosis. Phytomedicine. 2019;57:385–395.
   PubMed Web of Science ®Google Scholar
• Alshehri AS. Kaempferol attenuates diabetic nephropathy in streptozotocin-induced diabetic rats by a hypoglycaemic effect and concomitant activation of the Nrf-2/Ho-1/antioxidants axis. Arch Physiol Biochem. 2021;2021:1–14.
   Google Scholar
• Huang W, Liang Y, Dong J, et al. SUMO E3 ligase PIASy mediates high glucose-induced activation of NF-κB inflammatory signaling in rat mesangial cells. Mediators Inflamm. 2017;2017:1685194.
   PubMed Web of Science ®Google Scholar
• Iyengar PV. Regulation of ubiquitin enzymes in the TGF-β pathway. Int J Mol Sci. 2017;18(4):877.
   PubMed Web of Science ®Google Scholar
• Iyengar PV, Jaynes P, Rodon L, et al. USP15 Regulates SMURF2 kinetics through C-lobe mediated deubiquitination. Sci Rep. 2015;5:14733.
   PubMed Web of Science ®Google Scholar
• Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000;12(1):1–13.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Gao K, Wang Y, et al. Resveratrol ameliorates diabetic nephropathy in rats through negative regulation of the p38 MAPK/TGF-β1 pathway. Exp Ther Med. 2017;13(6):3223–3230.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang L, Deng D, et al. Renalase protects against renal fibrosis by inhibiting the activation of the ERK signaling pathways. Int J Mol Sci. 2017;18(5):855.
   PubMed Web of Science ®Google Scholar
• Liu X, Lin L, Li Q, et al. ERK1/2 communicates GPCR and EGFR signaling pathways to promote CTGF-mediated hypertrophic cardiomyopathy upon Ang-II stimulation. BMC Mol Cell Biol. 2019;20(1):14.
   PubMedGoogle Scholar
• Zhu M, Wang H, Chen J, et al. Sinomenine improve diabetic nephropathy by inhibiting fibrosis and regulating the JAK2/STAT3/SOCS1 pathway in streptozotocin-induced diabetic rats. Life Sci. 2021;265:118855.
   PubMed Web of Science ®Google Scholar
• Yu J, Wu H, Liu Z-Y, et al. Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation. Int J Mol Med. 2017;40(4):1185–1193.
   PubMed Web of Science ®Google Scholar
• Chow F, Ozols E, Nikolic-Paterson DJ, et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65(1):116–128.
   PubMed Web of Science ®Google Scholar
• Hao W, Lin Y, Liqin T, et al. Berberine inhibits JAK2/STAT3 signaling pathway to alleviate high glucose induced podocyte EMT and apoptosis. Acta Universitatis Medicinalis Anhui. 2022;57(08):1189–1194.
   Google Scholar
• Dugan LL, You Y-H, Ali SS, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest. 2013;123(11):4888–4899.
   PubMed Web of Science ®Google Scholar
• Zhang B, Guo X, Li Y, et al. d-Chiro inositol ameliorates endothelial dysfunction via inhibition of oxidative stress and mitochondrial fission. Mol Nutr Food Res. 2017;61(8):mnfr.201600710.
   Web of Science ®Google Scholar
• Li F, Chen Y, Li Y, et al. Geniposide alleviates diabetic nephropathy of mice through AMPK/SIRT1/NF-κB pathway. Eur J Pharmacol. 2020;886:173449.
   PubMed Web of Science ®Google Scholar
• Wu L, Liu C, Chang D-Y, et al. The attenuation of diabetic nephropathy by annexin A1 via regulation of lipid metabolism through the AMPK/PPARα/CPT1b pathway. Diabetes. 2021;70(10):2192–2203.
   PubMed Web of Science ®Google Scholar
• Han Y-C, Tang S-Q, Liu Y-T, et al. AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice. Cell Death Dis. 2021;12(10):925.
   PubMed Web of Science ®Google Scholar
• Xiang L, Jiang P, Zhou L, et al. Additive effect of qidan dihuang grain, a traditional chinese medicine, and angiotensin receptor blockers on albuminuria levels in patients with diabetic nephropathy: a randomized, Parallel-Controlled trial. Evid Based Complement Alternat Med. 2016;2016:1064924.
   PubMed Web of Science ®Google Scholar
• Sun G-D, Li C-Y, Cui W-P, et al. Review of herbal traditional chinese medicine for the treatment of diabetic nephropathy. J Diabetes Res. 2016;2016:5749857.
   PubMed Web of Science ®Google Scholar
• Shi H, Deng P, Dong C, et al. Quality of evidence supporting the role of tripterygium glycosides for the treatment of diabetic kidney disease: an overview of systematic reviews and meta-analyses. Drug Des Devel Ther. 2022;16:1647–1665.
   PubMed Web of Science ®Google Scholar
• Tao M, Zheng D, Liang X, et al. Tripterygium glycoside suppresses epithelial‑to‑mesenchymal transition of diabetic kidney disease podocytes by targeting autophagy through the mTOR/Twist1 pathway. Mol Med Rep. 2021;24(2):592.
   PubMed Web of Science ®Google Scholar
• Ma Z-J, Zhang X-N, Li L, et al. Tripterygium glycosides tablet ameliorates renal tubulointerstitial fibrosis via the Toll-Like receptor 4/nuclear factor kappa B signaling pathway in High-Fat diet fed and Streptozotocin-Induced diabetic rats. J Diabetes Res. 2015;2015:390428.
   PubMed Web of Science ®Google Scholar
• Ma R, Liu L, Liu X, et al. Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy. Exp Ther Med. 2013;6(3):649–656.
   PubMed Web of Science ®Google Scholar
• Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects. Phytother Res. 2014;28(7):961–975.
   PubMed Web of Science ®Google Scholar
• Wang B, Chen S, Yan X, et al. The therapeutic effect and possible harm of puerarin for treatment of stage III diabetic nephropathy: a meta-analysis. Altern Ther Health Med. 2015;21(1):36–44.
   PubMed Web of Science ®Google Scholar
• Li X, Zhu Q, Zheng R, et al. Puerarin attenuates diabetic nephropathy by promoting autophagy in podocytes. Front Physiol. 2020;11:73.
   PubMed Web of Science ®Google Scholar
• Yuan Y, et al. Inhibition of puerarin on formation of advanced glycation end products in vivo and in vitro. Chinese Traditional and Herbal Drugs. 2017;48(07):1386–1390.
   Google Scholar
• Mao CP, Gu ZL. Puerarin reduces increased c-fos, c-jun, and type IV collagen expression caused by high glucose in glomerular mesangial cells. Acta Pharmacol Sin. 2005;26(8):982–986.
   PubMed Web of Science ®Google Scholar
• Liu X, Yao L, Sun D, et al. Effect of breviscapine injection on clinical parameters in diabetic nephropathy: a meta-analysis of randomized controlled trials. Exp Ther Med. 2016;12(3):1383–1397.
   PubMed Web of Science ®Google Scholar
• Xu X-X, Zhang W, Zhang P, et al. Superior renoprotective effects of the combination of breviscapine with enalapril and its mechanism in diabetic rats. Phytomedicine. 2013;20(10):820–827.
   PubMed Web of Science ®Google Scholar
• Jiang W, Li Z, Zhao W, et al. Breviscapine attenuatted contrast medium-induced nephropathy via PKC/Akt/MAPK signalling in diabetic mice. Am J Transl Res. 2016;8(2):329–341.
   PubMed Web of Science ®Google Scholar
• Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B, et al. Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double-blind placebo-controlled clinical trial. Diabetes Metab. 2019;45(1):53–59.
   PubMed Web of Science ®Google Scholar
• Hu H-C, Lei Y-H, Zhang W-H, et al. Antioxidant and anti-inflammatory properties of resveratrol in diabetic nephropathy: a systematic review and meta-analysis of animal studies. Front Pharmacol. 2022;13:841818.
   PubMed Web of Science ®Google Scholar
• Chang C-C, Chang C-Y, Wu Y-T, et al. Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. J Biomed Sci. 2011;18(1):47.
   PubMed Web of Science ®Google Scholar
• Xu X-H, Ding D-F, Yong H-J, et al. Resveratrol transcriptionally regulates miRNA-18a-5p expression ameliorating diabetic nephropathy via increasing autophagy. Eur Rev Med Pharmacol Sci. 2017;21(21):4952–4965.
   PubMed Web of Science ®Google Scholar
• Chen K-H, Hung C-C, Hsu H-H, et al. Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. Chem Biol Interact. 2011;190(1):45–53.
   PubMed Web of Science ®Google Scholar
• Qi M-Y, He Y-H, Cheng Y, et al. Icariin ameliorates streptozocin-induced diabetic nephropathy through suppressing the TLR4/NF-κB signal pathway. Food Funct. 2021;12(3):1241–1251.
   PubMed Web of Science ®Google Scholar
• Wang K, Zheng X, Pan Z, et al. Icariin prevents extracellular matrix accumulation and ameliorates experimental diabetic kidney disease by inhibiting oxidative stress via GPER mediated p62-Dependent Keap1 degradation and Nrf2 activation. Front Cell Dev Biol. 2020;8:559.
   PubMed Web of Science ®Google Scholar
• Qi M-Y, Liu H-R, Su Y-h, et al. Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats. J Ethnopharmacol. 2011;138(3):731–736.
   PubMed Web of Science ®Google Scholar
• Jia Z, Wang K, Zhang Y, et al. Icariin ameliorates diabetic renal tubulointerstitial fibrosis by restoring autophagy via regulation of the miR-192-5p/GLP-1R pathway. Front Pharmacol. 2021;12:720387.
   PubMed Web of Science ®Google Scholar
• Fallahzadeh MK, Dormanesh B, Sagheb MM, et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis. 2012;60(6):896–903.
   PubMed Web of Science ®Google Scholar
• Khazim K, Gorin Y, Cavaglieri RC, et al. The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo. Am J Physiol Renal Physiol. 2013;305(5):F691–700.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen L, Yang T. Silymarin nanoliposomes attenuate renal injury on diabetic nephropathy rats via co-suppressing TGF-β/Smad and JAK2/STAT3/SOCS1 pathway. Life Sci. 2021;271:119197.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye J, Cao Y, et al. Silibinin ameliorates diabetic nephropathy via improving diabetic condition in the mice. Eur J Pharmacol. 2019;845:24–31.
   PubMed Web of Science ®Google Scholar
• Jz AL, et al. Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKCβ/p(66)Shc axis and activation of FOXO-3a. J Nutr Biochem. 2021;87:108515.
   PubMed Web of Science ®Google Scholar
• Soetikno V, Watanabe K, Sari FR, et al. Curcumin attenuates diabetic nephropathy by inhibiting PKC-α and PKC-β1 activity in streptozotocin-induced type I diabetic rats. Mol Nutr Food Res. 2011;55(11):1655–1665.
   PubMed Web of Science ®Google Scholar
• Tu Q, Li Y, Jin J, et al. Curcumin alleviates diabetic nephropathy via inhibiting podocyte mesenchymal transdifferentiation and inducing autophagy in rats and MPC5 cells. Pharm Biol. 2019;57(1):778–786.
   PubMed Web of Science ®Google Scholar
• Tikoo K, Meena RL, Kabra DG, et al. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br J Pharmacol. 2008;153(6):1225–1231.
   PubMed Web of Science ®Google Scholar
• Voroneanu L, Siriopol D, Dumea R, et al. Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial. Int Urol Nephrol. 2017;49(12):2195–2204.
   PubMed Web of Science ®Google Scholar
• Wang X, Xu Y, Chu C, et al. Effect of safflower yellow on early type II diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials. J Pediatr Endocrinol Metab. 2019;32(7):653–665.
   PubMed Web of Science ®Google Scholar
• Du M, Hu X, Kou L, et al. Lycium barbarum polysaccharide mediated the antidiabetic and antinephritic effects in Diet-Streptozotocin-induced diabetic Sprague Dawley rats via regulation of NF-κB. Biomed Res Int. 2016;2016:3140290.
   PubMed Web of Science ®Google Scholar
• Wan F, Ma F, Wu J, et al. Effect of Lycium Barbarum polysaccharide on decreasing serum amyloid A3 expression through inhibiting NF-κB activation in a mouse model of diabetic nephropathy. Anal Cell Pathol. 2022;2022:1–12.
   Web of Science ®Google Scholar
• Zhao R, Li Q-W, Li J, et al. Protective effect of Lycium barbarum polysaccharide 4 on kidneys in streptozotocin-induced diabetic rats. Can J Physiol Pharmacol. 2009;87(9):711–719.
   PubMed Web of Science ®Google Scholar
• Fu-Tuan G, et al. The anti-oxidative effect of ramulus mori polysaccharides on diabetic nephropathy mice. Chin Pharmacol Bull. 2016;32(08):1148–1152.
   Google Scholar
• Xiao-Ling G, et al. Effect of astragalus polysaccharides on apoptosis, transdifferentiation and ROS content in renal tubular epithelial cells of diabetic nephropathy. Chin J Immunol. 2018;34(03):388–392.
   Google Scholar
• Cheng-de L, et al. Effects of astragalus polysaccharide on renal TGF-β1/smads signaling pathway in rats with diabetes mellitus. Chin Pharmacol Bull. 2018;34(04):512–516.
   Google Scholar
• Qin X, Zhao Y, Gong J, et al. Berberine protects glomerular podocytes via inhibiting Drp1-mediated mitochondrial fission and dysfunction. Theranostics. 2019;9(6):1698–1713.
   PubMed Web of Science ®Google Scholar
• Pang B, Zhao L-H, Zhou Q, et al. Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol. 2015;2015:905749.
   PubMed Web of Science ®Google Scholar
• Ni WJ, Ding HH, Tang LQ. Berberine as a promising anti-diabetic nephropathy drug: an analysis of its effects and mechanisms. Eur J Pharmacol. 2015;760:103–112.
   PubMed Web of Science ®Google Scholar
• Zhao H-L, Sui Y, Qiao C-F, et al. Sustained antidiabetic effects of a berberine-containing chinese herbal medicine through regulation of hepatic gene expression. Diabetes. 2012;61(4):933–943.
   PubMed Web of Science ®Google Scholar
• Wang FL, Tang LQ, Yang F, et al. Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. Mol Biol Rep. 2013;40(3):2405–2418.
   PubMed Web of Science ®Google Scholar
• Zhang X, He H, Liang D, et al. Protective effects of berberine on renal injury in streptozotocin (STZ)-induced diabetic mice. Int J Mol Sci. 2016;17(8):1327.
   PubMed Web of Science ®Google Scholar
• Qin X, Jiang M, Zhao Y, et al. Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis. Br J Pharmacol. 2020;177(16):3646–3661.
   PubMed Web of Science ®Google Scholar
• Zhu L, Han J, Yuan R, et al. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. Biol Res. 2018;51(1):9.
   PubMedGoogle Scholar
• Wang B, Ni Q, Wang X, et al. Meta-analysis of the clinical effect of ligustrazine on diabetic nephropathy. Am J Chin Med. 2012;40(1):25–37.
   PubMed Web of Science ®Google Scholar
• Xie F, Zhang B, Dai S, et al. Efficacy and safety of Salvia miltiorrhiza (Salvia miltiorrhiza Bunge) and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease: a systematic review and meta-analysis. J Ethnopharmacol. 2021;281:114346.
   PubMed Web of Science ®Google Scholar
• Zhuang Z, Wang Z-H, Huang Y-Y, et al. Protective effect and possible mechanisms of ligustrazine isolated from Ligusticum wallichii on nephropathy in rats with diabetes: a preclinical systematic review and meta-analysis. J Ethnopharmacol. 2020;252:112568.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shergis JL, Yang L, et al. Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: an updated systematic review and meta-analysis. J Ethnopharmacol. 2019;239:111921.
   PubMed Web of Science ®Google Scholar
• Xuqin D, et al. Astragalus injection for early diabetic nephropathoes:a meta-analysis. Chin Arch Trad Chin Med. 2019;37(04):869–872.
   Google Scholar
• Li M, Wang W, Xue J, et al. Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy. J Ethnopharmacol. 2011;133(2):412–419.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhuang Z, Huang Y-Y, et al. Protective effect and possible mechanisms of astragaloside IV in animal models of diabetic nephropathy: a preclinical systematic review and meta-Analysis. Front Pharmacol. 2020;11:988.
   PubMed Web of Science ®Google Scholar
• Wang Q, Shao X, Xu W, et al. Astragalosides IV inhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epithelial cells. Ren Fail. 2014;36(3):400–406.
   PubMed Web of Science ®Google Scholar
• Su J, Gao C, Xie L, et al. Astragaloside II ameliorated podocyte injury and mitochondrial dysfunction in streptozotocin-induced diabetic rats. Front Pharmacol. 2021;12:638422.
   PubMed Web of Science ®Google Scholar
• Guo H, Wang Y, Zhang X, et al. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy. Sci Rep. 2017;7(1):6852.
   PubMedGoogle Scholar
• Wang X, Gao Y, Tian N, et al. Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB p65 subunit. Drug Des Devel Ther. 2018;12:2971–2980.
   PubMed Web of Science ®Google Scholar
• Feng H, Zhu X, Tang Y, et al. Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome‑mediated inflammation. Int J Mol Med. 2021;48(2):164.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhu Q, Shao Y, et al. Paeoniflorin prevents TLR2/4-mediated inflammation in type 2 diabetic nephropathy. Biosci Trends. 2017;11(3):308–318.
   PubMed Web of Science ®Google Scholar
• Li X, Wang Y, Wang K, et al. Renal protective effect of Paeoniflorin by inhibition of JAK2/STAT3 signaling pathway in diabetic mice. Biosci Trends. 2018;12(2):168–176.
   PubMed Web of Science ®Google Scholar
• Zhang M-h, Feng L, Zhu M-M, et al. Antioxidative and anti-inflammatory activities of paeoniflorin and oxypaeoniflora on AGEs-induced mesangial cell damage. Planta Med. 2013;79(14):1319–1323.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhao D, Zhu M, et al. Paeoniflorin ameliorates AGEs-induced mesangial cell injury through inhibiting RAGE/mTOR/autophagy pathway. Biomed Pharmacother. 2017;89:1362–1369.
   PubMed Web of Science ®Google Scholar
• Wang H, Teng Y, Li S, et al. UHPLC-MS-Based serum and urine metabolomics reveals the anti-diabetic mechanism of ginsenoside re in type 2 diabetic rats. Molecules. 2021;26(21):6657.
   PubMed Web of Science ®Google Scholar
• He J-Y, Hong Q, Chen B-X, et al. Ginsenoside Rb1 alleviates diabetic kidney podocyte injury by inhibiting aldose reductase activity. Acta Pharmacol Sin. 2022;43(2):342–353.
   PubMed Web of Science ®Google Scholar
• Shi Y, Gao Y, Wang T, et al. Ginsenoside Rg1 alleviates podocyte EMT passage by regulating AKT/GSK3 β/β-Catenin pathway by restoring autophagic activity. Evid Based Complement Alternat Med. 2020;2020:1903627.
   PubMed Web of Science ®Google Scholar
• Liu H, Chen W, Lu P, et al. Ginsenoside Rg1 attenuates the inflammation and oxidative stress induced by diabetic nephropathy through regulating the PI3K/AKT/FOXO3 pathway. Ann Transl Med. 2021;9(24):1789.
   PubMed Web of Science ®Google Scholar
• Du N, Xu Z, Gao M, et al. Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling Cascade on renal fibrosis in rats with diabetic nephropathy. Drug Des Devel Ther. 2018;12:3517–3524.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhu C, Yang H, et al. Protective effect of ginsenoside Rg5 against kidney injury via inhibition of NLRP3 inflammasome activation and the MAPK signaling pathway in high-fat diet/streptozotocin-induced diabetic mice. Pharmacol Res. 2020;155:104746.
   PubMed Web of Science ®Google Scholar
• Tu QN, Dong H, Lu FE. Effects of Panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus. Chin J Integr Med. 2011;17(8):612–615.
   PubMed Web of Science ®Google Scholar
• Yang J, Zeng Z, Wu T, et al. Emodin attenuates high glucose-induced TGF-β1 and fibronectin expression in mesangial cells through inhibition of NF-κB pathway. Exp Cell Res. 2013;319(20):3182–3189.
   PubMed Web of Science ®Google Scholar
• Tian N, Gao Y, Wang X, et al. Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy. Drug Des Devel Ther. 2018;12:2195–2211.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang Q, Shi G, et al. Emodin ameliorates renal damage and podocyte injury in a rat model of diabetic nephropathy via regulating AMPK/mTOR-mediated autophagy signaling pathway. Diabetes Metab Syndr Obes. 2021;14:1253–1266.
   PubMed Web of Science ®Google Scholar
• Jing D, Bai H, Yin S. Renoprotective effects of emodin against diabetic nephropathy in rat models are mediated via PI3K/Akt/GSK-3β and Bax/caspase-3 signaling pathways. Exp Ther Med. 2017;14(5):5163–5169.
   PubMed Web of Science ®Google Scholar
• Yan M, Wen Y, Yang L, et al. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial. Trials. 2016;17(1):259.
   PubMedGoogle Scholar
• Hu J, Fan X, Meng X, et al. Evidence for the involvement of JAK/STAT/SOCS pathway in the mechanism of Tangshen formula-treated diabetic nephropathy. Planta Med. 2014;80(8–9):614–621.
   PubMed Web of Science ®Google Scholar
• An W, Huang Y, Chen S, et al. Efficacy and safety of Huangkui capsule for diabetic nephropathy: a protocol for systematic review and meta-analysis. Medicine. 2021;100(42):e27569. ),
   PubMed Web of Science ®Google Scholar
• Cai H-D, Su S-L, Qian D-W, et al. Renal protective effect and action mechanism of Huangkui capsule and its main five flavonoids. J Ethnopharmacol. 2017;206:152–159.
   PubMed Web of Science ®Google Scholar
• Gu L-Y, Tang H-T, Xu Z-X, et al. Huangkui capsule in combination with metformin ameliorates diabetic nephropathy via the Klotho/TGF-β1/p38MAPK signaling pathway. J Ethnopharmacol. 2021;281:113548.
   PubMed Web of Science ®Google Scholar
• Ge J, Miao J-J, Sun X-Y, et al. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats. J Ethnopharmacol. 2016;189:238–249.
   PubMed Web of Science ®Google Scholar
• Ma J, Xu L, Dong J, et al. Effects of zishentongluo in patients with early-stage diabetic nephropathy. Am J Chin Med. 2013;41(2):333–340.
   PubMed Web of Science ®Google Scholar
• Hsu P-C, Tsai Y-T, Lai J-N, et al. Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study. J Ethnopharmacol. 2014;156:358–364.
   PubMed Web of Science ®Google Scholar
• Chen HH, Wu C-T, Tsai Y-T, et al. Liu Wei Di Huang Wan and the Delay of insulin use in patients with type 2 diabetes in Taiwan: a nationwide study. Evid Based Complement Alternat Med. 2021;2021:1298487.
   PubMed Web of Science ®Google Scholar
• Song XY, Chen Q, Qi XY. Effect of Liuwei Dihuang Pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004;24(12):1087–1090.
   PubMedGoogle Scholar
• Renzhi J, et al. Clinical efficacy of wuling powder combined with rosiglitazone on diabetic nephropathy. Pharma Clin Chin Materia Medica. 2017;33(04):176–178.
   Google Scholar
• Liu I-M, Tzeng T-F, Liou S-S, et al. The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription. J Ethnopharmacol. 2009;124(2):211–218.
   PubMed Web of Science ®Google Scholar
• Xi-Mou Z, et al. Fermented cordyceps powder combined with ACEI/ARB in treatment of diabetic kidney disease:a systematic review. Chin J Exp Trad Med Form. 2021;27(18):169–175.
   Google Scholar
• Haotao M. Effects of Jinshuibao capsule combined with compound α-keto acid tablets on endothelial function and renal artery blood flow in patients with diabetic nephropathy. Pract Clin J Integr Trad Chin Western Med. 2022;22(07):27–30.
   Google Scholar
• Lu Q, Li C, Chen W, et al. Clinical efficacy of Jinshuibao capsules combined with angiotensin receptor blockers in patients with early diabetic nephropathy: a meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2018;2018:6806943.
   PubMed Web of Science ®Google Scholar
• Sun WS, Wu XL, Qiao CL. [Clinical study on effect of tongluo capsule in treating diabetic nephropathy caused chronic renal failure. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004;24(8):704–706.
   PubMedGoogle Scholar
• Li B-y, Peng H, Xiong D-L, et al. Efficacy observation of treating diabetic nephropathy by shenshuaining granule combined telmisartan tablet. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(2):142–146.
   PubMedGoogle Scholar
• Liu S, Tang L-Q, Chen L-M, et al. Effect of compound Rhizoma Coptidis capsule on expression of transforming growth factor-beta1 and type IV collagen proteins in renal tissue of diabetic rats with nephropathy. Zhongguo Zhong Yao Za Zhi. 2008;33(1):68–72.
   PubMedGoogle Scholar
• Guo Z-A, Yu C-J, Liu G, et al. Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014;34(9):1047–1052.
   PubMedGoogle Scholar
• Li MZ, Gao YB, Ma MF. Effects of qiwei granule on the protein and mRNA expressions of renal tissue transforming growth factor-beta1 in KK-Ay mice with spontaneous type 2 diabetes mellitus. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012;32(12):1675–1678.
   PubMedGoogle Scholar
• Zhao TT, Zhang HJ, Lu XG, et al. Chaihuang-Yishen granule inhibits diabetic kidney disease in rats through blocking TGF-β/Smad3 signaling. PLoS One. 2014;9(3):e90807.
   PubMed Web of Science ®Google Scholar
• Ma F, Li L, Wang Q, et al. Qi-dan-di-huang decoction alleviates diabetic nephropathy by inhibiting the NF-kappaB pathway. Front Biosci. 2019;24(8):1477–1486.
   Google Scholar
• Liu I-M, Tzeng T-F, Liou S-S, et al. Beneficial effect of traditional chinese medicinal formula danggui-shaoyao-san on advanced glycation end-product-mediated renal injury in streptozotocin-diabetic rats. Evid Based Complement Alternat Med. 2012;2012:140103.
   PubMed Web of Science ®Google Scholar
• Fang D, Wan X, Deng W, et al. Fufang Xue Shuan Tong capsules inhibit renal oxidative stress markers and indices of nephropathy in diabetic rats. Exp Ther Med. 2012;4(5):871–876.
   PubMed Web of Science ®Google Scholar